Skip to main content

Table 1 Background of patients

From: Survival and predictive factors in dialysis patients with COVID-19 in Japan: a nationwide cohort study

  Recovered Died p valuea
n % n %
Age
  < 60 250 35.8 29 9.3 < 0.001
 60 s 164 23.5 45 14.5  
 ≥ 70 285 40.8 237 76.2  
Gender
 Male 497 71.3 212 68.4 0.37
 Female 200 28.7 98 31.6  
Primary disease
 Chronic glomerulonephritis 123 19.4 37 13.8 0.211
 Diabetes mellitus 328 51.8 147 54.6  
 Nephrosclerosis 87 13.7 43 16.0  
 Others 95 15.0 42 15.6  
Duration of dialysis
 < 1 year 95 13.9 21 7.5 0.015
 1 to < 5 years 257 37.6 94 33.7  
 5 to < 10 years 164 24.0 78 28.0  
 10 to < 15 years 83 12.1 45 16.1  
 ≥ 15 years 85 12.4 41 14.7  
Complication
 Hypertension
  No 383 56.2 158 57.0 0.83
  Yes 299 43.8 119 43.0  
 Diabetes mellitus
  No 335 48.4 120 42.7 0.119
  Yes 357 51.6 161 57.3  
 Cardiovascular disease
  No 420 62.5 131 48.9 < 0.001
  Yes 252 37.5 137 51.1  
 Chronic respiratory disease
  No 625 92.5 243 89.3 0.122
  Yes 51 7.5 29 10.7  
 Peripheral arterial disease
  No 585 87.3 198 74.7 < 0.001
  Yes 85 12.7 67 25.3  
 Malignancy
  No 586 86.8 226 84.0 0.298
  Yes 89 13.2 43 16.0  
 Number of complications
 0 114 16.5 29 10.2 0.008
 1 218 31.5 80 28.2  
 ≥ 2 361 52.1 175 61.6  
Oxygenation
 No 302 44.8 29 10.5 < 0.001
 Yes 320 47.5 174 63.0  
 Ventilator or ECMO 52 7.7 73 26.4  
Remdesivir
 No 591 89.0 235 90.0 0.723
 Yes 73 11.0 26 10.0  
Dexamethasone
 No 374 56.2 107 40.5 < 0.001
 Yes 291 43.8 157 59.5  
  1. ECMO extracorporeal membrane oxygenation
  2. aFisher’s exact test